Empagliflozin

Indication

Monotherapy for treating type 2 diabetes (NICE TA390)

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Green

Brand:

Jardiance®

Nice TA:

390

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:

Endocrine system

Background

Canagliflozin, dapagliflozin and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:

a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and
a sulfonylurea or pioglitazone is not appropriate.

The LSCMMG recommends empagliflozin as a 1^st line ““gliflozin””.

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

Algorithm For Antihyperglycaemic Therapy In Adults With Type II (Version 1.5)

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Green	Green	Green	Green	Green	Green	Green	Green

What do the colours mean?

Last Updated: 01 - Jun - 2016